AMGN News 133.02 08/20/2014 04:32:33 Amgen Inc (AMGN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amgen Inc (AMGN) 133.02 $AMGN

Final Glance: Biotechnology companies
AP - Tue Aug 19, 5:09PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 4:25PM CDT
Amgen Inc. (AMGN) announced that AMG 416 has met the primary as well as secondary endpoints in the second phase III registration study.

Midday Glance: Biotechnology companies
AP - Tue Aug 19, 3:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:

14.4% Return Seen to Date on SmarTrend Amgen Call (AMGN)
Comtex SmarTrend(R) - Tue Aug 19, 9:42AM CDT
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on June 2nd, 2014 at $116.45. In approximately 3 months, Amgen has returned 14.41% as of today's recent price of $133.22.

A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.

Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
PR Newswire - Tue Aug 19, 12:55AM CDT
Gamida Cell, a world leader in stem cell expansion technologies and therapeutic products, announced today that it has signed an investment and option agreement with Novartis Pharma AG ("Novartis" . According to the agreement, Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement of certain milestones connected to the development of NiCord®, anticipated to be met during 2015. Completion of the transaction is subject to customary closing conditions.

3 Reasons Amgen, Inc.'s Stock Could Rise
Sean Williams, The Motley Fool - Motley Fool - Mon Aug 18, 5:13PM CDT
As you can see below, Amgen shareholders have had a great three years, with Amgen's stock having risen by more than 160%. AMGN data by YCharts The company's second-quarter earnings results, released three weeks ago, prove testament...

Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis
PR Newswire - Mon Aug 18, 4:17PM CDT
Amgen (NASDAQ:AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. These results follow the recent announcement of positive data from a prior placebo-controlled Phase 3 study of AMG 416 which was similar in design and size.

Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.

Earnings Look Back: Amgen Is Up 7.7% Since Reporting Quarterly Results 2 Weeks Ago (AMGN)
Comtex SmarTrend(R) - Mon Aug 18, 9:32AM CDT
20 days ago, on July 29th, 2014, Amgen (NASDAQ:AMGN) reported its earnings. Analysts, on average, expected earnings of $2.07 per share on sales of $4.9 billion. Amgen actually reported earnings of $2.37 per share on sales of $5.2 billion, beating EPS estimates by $0.30 and beating revenue estimates by $279.7 million. Shares of Amgen have climbed from $123.31 to $132.80, representing a gain of 7.7% since the company reported earnings 20 days ago.

Early Glance: Biotechnology companies
AP - Mon Aug 18, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:

The Zacks Analyst Blog Highlights: Amgen, ANN, Citi Trends, Men's Wearhouse and Kate Spade
PR Newswire - Fri Aug 15, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen (Nasdaq:AMGN-Free Report), ANN Inc. (NYSE:ANN-Free Report), Citi Trends Inc. (Nasdaq:CTRN-Free Report), Men's Wearhouse Inc. (NYSE:MW-Free Report) and Kate Spade & Co. (NYSE:KATE-Free Report).

Biotech Stock Mailbag: Exact Sciences, Galena, Amgen
at The Street - Fri Aug 15, 6:22AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.

Global Biological Drugs Market 2014 - 2020 - Industry Analysis for the $161.056 Million Industry
M2 - Fri Aug 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjz57l/biological_drugs) has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global biological drugs market is estimated at USD 161,056.5 million in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach USD 287,139.7 million by 2020 The report provides in-depth analysis and estimation of the biological drugs market from 2014 to 2020, considering 2013 as the base year for calculation. Additionally, data pertaining to current market dynamics including market drivers, restraints, trends and recent developments has been provided in the biological drugs market report. The global biological drugs market is categorized based on therapeutic protein, monoclonal antibody (mAb), vaccine and geography. The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea. The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax and Cervarix. Globally, the biological drugs market is witnessing a significant growth due to increasing prevalence of various chronic diseases, as the demand for biological drugs is increasing with the rise in the global geriatric population. The biological drugs are used in the treatment and prevention of various diseases, such as blood related diseases, cancer, auto-immune diseases and other medical disorders. Additionally, various government associations are promoting the usage of biological drugs. Moreover, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market. North America is the largest market for biological drugs. Enbrel is the largest and fastest growing therapeutic protein. In monoclonal antibody (mAb), Humira is the largest and fastest growing mAb. Prevnar 13 is the largest and fastest growing vaccine. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Biological Drugs Market - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Forces Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis, by Therapeutic Protein Chapter 8 Segment Analysis, by mAb Chapter 9 Segment Analysis, by Vaccine Chapter 10 Regional Analysis Chapter 11 Pipeline Biologic Drugs Chapter 12 Competitive Landscape Chapter 13 Company Profiles - Abbott Laboratories - Amgen Inc. - Baxter International Inc. - Biogen Idec - Bristol-Myers Squibb Company - Eli Lilly and Company - GlaxoSmithKline plc. - Merck & Co., Inc. - Novartis AG - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/hj...ical_drugs

Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 4:20PM CDT
Amgen (AMGN) suffered a major setback when its phase III study, FOCUS on multiple myeloma treatment, Kyprolis did not meet its primary endpoint.

After Yesterday's Rally of 3.55% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Aug 14, 3:39PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $124.81 to a high of $132.52. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $128.00 on volume of 6.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 326

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 0

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 31

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 117

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 419

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading

Top 5 Most Recently Viewed Articles

Inventiva's Significant Capital Boost Through Public Offering

Updated Category News Views 276

Inventiva's Upsized Public Offering Explained Inventiva, a clinical-stage biopharmaceutical company known for its focus on developing oral therapies targeting metabolic disorders, has recently announced the pricing details of its public offering. This significant initiative is set to raise around $150 million by selling approximately 38.96 million American Depositary...

Continue Reading
The Future of AI: How Innovations Drive Market Growth

Updated Category News Views 264

AI Market Growth Overview The artificial intelligence (AI) market is set for substantial growth, projected to increase by USD 237.4 billion from 2024 to 2028. The forecast indicates a remarkable compound annual growth rate (CAGR) of 30.07% during this period. This growth can largely be attributed to the rising demand for effective solutions in fraud prevention and the...

Continue Reading
commercetools Compilations: Innovations Driving Digital Growth

Updated Category News Views 177

Exciting Launch of commercetools Compilations commercetools has unveiled Compilations, a semi-annual showcase that highlights more than 50 product enhancements, demonstrating the organization’s dedication to innovation and improved customer experiences for users of the commercetools Platform. With over 13,000 deployments and 200 releases, this initiative significantly...

Continue Reading
AKOOL's Agentic Canvas: AI Execution Revolution

Updated Category News Views 23

AKOOL Elevates AI from Chat to Execution Well, folks, it looks like AKOOL is shaking things up in the world of artificial intelligence. Forget about AI that's just about chatting away and searching for answers like a digital gopher. This time, AKOOL is bringing something new to the table with its Agentic Canvas, and it's a real game-changer for anyone still fooling around...

Continue Reading
Qudian Inc. Transitions to High Templar Tech Limited

Updated Category News Views 222

Qudian Inc. Transitions to High Templar Tech Limited Qudian Inc., a technology-driven consumer company in China, has officially announced its rebranding to High Templar Tech Limited along with a change in its stock ticker from "QD" to "HTT". This significant decision reflects the company's evolving strategy and commitment to enhancing consumer experiences through...

Continue Reading